Johns Hopkins Medicine has become the latest academic medical center to acquire the Naviscan Positron Emission Mammography (PEM) scanner. The device will be utilized by Richard Wahl, M.D., F.A.C.R, Professor of Radiology and Nuclear Medicine at the Johns Hopkins University School of Medicine, in pre-clinical and translational research for the development of novel radiotracers.
"As the use of Naviscan's organ-specific PET imaging technology continues to be used in cutting-edge breast cancer research and clinical patient management, Naviscan is also developing its use in new clinical applications. As a result, the development and clinical validation of novel radiotracers is essential," said Paul J. Mirabella, Chairman and CEO, Naviscan, Inc.
Dr. Wahl patented the technology which enabled Naviscan to develop the first and only FDA-cleared PET-guided biopsy accessory, known as Stereo Navigator®. Naviscan obtained an exclusive license to this patent, which Wahl developed while he was at the University of Michigan.
Other academic medical centers utilizing Naviscan's PEM technology include University of Cincinnati, Baylor University, M.D. Anderson, University of Chicago, and the Boston University Medical Center.
Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy